Neutral
Johnson & Johnson's stock drops 1.69% to €226.93 amid new psoriasis treatment data
In the past 24 hours, Johnson & Johnson's stock declined by 1.69% to €226.93 following the release of two-year data from the Phase 3 ICONIC-TOTAL study on ICOTYDE (Icotrokinra) for plaque psoriasis. The study reported that 70% of treated patients achieved clear or almost clear skin at week 112, with complete healing rates of 60% on the scalp, 89% in the genital area, and 63% on hands and feet. Safety data remained consistent with known profiles, with no new safety signals identified.
Key points
- Johnson & Johnson's stock declined by 1.69% to €226.93 following the release of new psoriasis treatment data.
- The Phase 3 ICONIC-TOTAL study showed 70% of patients achieved clear or almost clear skin at week 112.
- Complete healing rates were 60% on the scalp, 89% in the genital area, and 63% on hands and feet.
- Safety data remained consistent with known profiles, with no new safety signals identified.
Sources
AI-generated from public news sources. Not financial advice.
